Skip to main content

Home/ Dr. Goodyear/ Group items tagged combined

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Combination L-T3 and L-T4... [Curr Opin Endocrinol Diabetes Obes. 2013] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...23974776

hypothyroid hypothyroidism T4 T3 thyroid therapy

shared by Nathan Goodyear on 09 Sep 13 - No Cached
  • Nathan Goodyear on 09 Sep 13
     
    This article reviews the genetic polymorphisms that play role in low T4 to T3 conversion and thus combination T4/T3 therapy is indicated.  This study fails to recognize the environmental impacts on the deiodinase enzymes.
Nathan Goodyear

JISSN | Full text | International Society of Sports Nutrition position stand: creatine ... - 0 views

www.jissn.com/6

creatine sports nutrition exercise

shared by Nathan Goodyear on 27 Jan 14 - No Cached
  • the energy supplied to rephosphorylate adenosine diphosphate (ADP) to adenosine triphosphate (ATP) during and following intense exercise is largely dependent on the amount of phosphocreatine (PCr) stored in the muscle
  • Creatine is chemically known as a non-protein nitrogen
  • It is synthesized in the liver and pancreas from the amino acids arginine, glycine, and methionine
  • ...26 more annotations...
  • Approximately 95% of the body's creatine is stored in skeletal muscle
  • About two thirds of the creatine found in skeletal muscle is stored as phosphocreatine (PCr) while the remaining amount of creatine is stored as free creatine
  • The body breaks down about 1 – 2% of the creatine pool per day (about 1–2 grams/day) into creatinine in the skeletal muscle
  • The magnitude of the increase in skeletal muscle creatine content is important because studies have reported performance changes to be correlated to this increase
  • "loading" protocol. This protocol is characterized by ingesting approximately 0.3 grams/kg/day of CM for 5 – 7 days (e.g., ≃5 grams taken four times per day) and 3–5 grams/day thereafter [18,22]. Research has shown a 10–40% increase in muscle creatine and PCr stores using this protocol
  • Additional research has reported that the loading protocol may only need to be 2–3 days in length to be beneficial, particularly if the ingestion coincides with protein and/or carbohydrate
  • A few studies have reported protocols with no loading period to be sufficient for increasing muscle creatine (3 g/d for 28 days)
  • Cycling protocols involve the consumption of "loading" doses for 3–5 days every 3 to 4 weeks
  • Most of these forms of creatine have been reported to be no better than traditional CM in terms of increasing strength or performance
  • Recent studies do suggest, however, that adding β-alanine to CM may produce greater effects than CM alone
  • These investigations indicate that the combination may have greater effects on strength, lean mass, and body fat percentage; in addition to delaying neuromuscular fatigue
  • creatine phosphate has been reported to be as effective as CM at improving LBM and strength
  • Green et al. [24] reported that adding 93 g of carbohydrate to 5 g of CM increased total muscle creatine by 60%
  • Steenge et al. [23] reported that adding 47 g of carbohydrate and 50 g of protein to CM was as effective at promoting muscle retention of creatine as adding 96 g of carbohydrate.
  • It appears that combining CM with carbohydrate or carbohydrate and protein produces optimal results
  • Studies suggest that increasing skeletal muscle creatine uptake may enhance the benefits of training
  • Nearly 70% of these studies have reported a significant improvement in exercise capacity,
  • Long-term CM supplementation appears to enhance the overall quality of training, leading to 5 to 15% greater gains in strength and performance
  • Nearly all studies indicate that "proper" CM supplementation increases body mass by about 1 to 2 kg in the first week of loading
  • short-term adaptations reported from CM supplementation include increased cycling power, total work performed on the bench press and jump squat, as well as improved sport performance in sprinting, swimming, and soccer
  • Long-term adaptations when combining CM supplementation with training include increased muscle creatine and PCr content, lean body mass, strength, sprint performance, power, rate of force development, and muscle diameter
  • subjects taking CM typically gain about twice as much body mass and/or fat free mass (i.e., an extra 2 to 4 pounds of muscle mass during 4 to 12 weeks of training) than subjects taking a placebo
  • The gains in muscle mass appear to be a result of an improved ability to perform high-intensity exercise via increased PCr availability and enhanced ATP synthesis, thereby enabling an athlete to train harder
  • there is no evidence to support the notion that normal creatine intakes (< 25 g/d) in healthy adults cause renal dysfunction
  • no long-term side effects have been observed in athletes (up to 5 years),
  • One cohort of patients taking 1.5 – 3 grams/day of CM has been monitored since 1981 with no significant side effects
  • Nathan Goodyear on 27 Jan 14
     
    Nice review of the data, up to the publication date, on creatine.
Nathan Goodyear

Effects of tibolone and combined 17β-estradiol and norethisterone acetate on ... - 0 views

humrep.oxfordjournals.org/...2748.full

estradiol progestin hormone hormones HRT CRP women

shared by Nathan Goodyear on 17 Nov 13 - No Cached
  • Nathan Goodyear on 17 Nov 13
     
    Study finds that estradiol combined with synthetic progestin increased CRP.  No surprise.
Nathan Goodyear

Targeting Synaptic Dysfunction in Alzheimer's Disease by Administering a Specific Nutri... - 0 views

iospress.metapress.com/...gg33167h46757165

alzheimer's disease Alzheimer's disease DHA EPA Folate B12 B6 vitamin E C vitamins brain

shared by Nathan Goodyear on 04 Dec 13 - No Cached
  • Nathan Goodyear on 04 Dec 13
     
    Combination of DHA, EPA, choline, phospholipids, Folate, B12, B6, vitamin C and E, and selenium improves memory and cognitive function in those with mild Alzheimer's disease.
Nathan Goodyear

The Combined therapy myo-inositol ... [Eur Rev Med Pharmacol Sci. 2013] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...23467955

PCOS polycystic ovarian syndrome d-chiro-inositol myo-inositol

shared by Nathan Goodyear on 20 Dec 13 - No Cached
  • Nathan Goodyear on 20 Dec 13
     
    Combination therapy of d-chiro-inositol and myo-inositol improve metabolic markers of PCOS.
Nathan Goodyear

Informa Healthcare - Journal of Nutritional and Environmental Medicine - 11(3):159 - Su... - 0 views

informahealthcare.com/...13590840120083376

hypothyroid hypothyroidism armour thyroid synthroid

shared by Nathan Goodyear on 20 Dec 10 - No Cached
  • Conclusions: Combined T3 + T4 treatment seems to be more effective than treatment with T4 alone in hypothyroid patients
  • Nathan Goodyear on 20 Dec 10
     
    patients on synthroid only improved when switch to combined T4/T3 (armour thyroid)
Nathan Goodyear

Unequal risks for breast cancer associated with di... [Breast Cancer Res Treat. 2008] -... - 0 views

www.ncbi.nlm.nih.gov/...17333341

bioidentical progesterone breast cancer risk

shared by Nathan Goodyear on 30 Mar 11 - No Cached
  • The association of estrogen-progestagen combinations with breast cancer risk varied significantly according to the type of progestagen: the relative risk was 1.00 (0.83-1.22) for estrogen-progesterone, 1.16 (0.94-1.43) for estrogen-dydrogesterone, and 1.69 (1.50-1.91) for estrogen combined with other progestagens.
  • These findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone
  • Nathan Goodyear on 30 Mar 11
     
    progesterone shows no increased risk of breast cancer; compared to synthetic progestins significantly increased risk
Nathan Goodyear

Combined conjugated esterified estrogen plus methyltestosterone sup... - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...25011395

breast cancer cancer Estrogen Testosterone women hormones hormone HRT

shared by Nathan Goodyear on 06 Feb 15 - No Cached
  • Nathan Goodyear on 06 Feb 15
     
    10 year f/u study of combined conjugated esterified estrogen and methyl testosterone in postmenopausal women finds no increase breast cancer risk.
Nathan Goodyear

Risk of Breast Cancer in Relation to Combined Effects of Hormone Th... - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...25695354

breast cancer cancer women hormones hormone Testosterone Estrogen Estradiol ER+ estrogen receptors obesity overweight hormone therapy

shared by Nathan Goodyear on 23 Feb 15 - No Cached
  • Nathan Goodyear on 23 Feb 15
     
    Study finds increases serum Estradiol and Testosterone levels associated with increased risk of breast cancer.  Increased risk was also found associated with being overweight/obese, increased alcohol intake, alcohol combined with HT.  This was found in estrogen receptor + cases of breast cancer.
Nathan Goodyear

A combination of green tea extract and l-theanine improves memory and attention in subj... - 0 views

www.ncbi.nlm.nih.gov/...21303262

l-theanine EGCG green tea extract memory cognition brain

shared by Nathan Goodyear on 20 Feb 16 - No Cached
  • Nathan Goodyear on 20 Feb 16
     
    combination of l-Theanine and EGCT improve cognition.
Nathan Goodyear

Genetic Determinants of Serum Testosterone Concentrations in Men - 0 views

www.ncbi.nlm.nih.gov/...PMC3188559

epigenetics low Testosterone SNPs Testosterone

shared by Nathan Goodyear on 19 Sep 17 - No Cached
  • mean serum testosterone concentrations were found to be lower in men with GG than in those with TT genotype for rs12150660
  • men with the CT genotype for rs6258 had lower serum testosterone concentrations than those with CC genotype.
  • The two autosomal SNPs identified by GWAS had a significant influence on the risk of having low serum testosterone (serum testosterone <300 ng/dl) in both the discovery and the replication cohorts with a combined odds ratio (OR) per minor allele of 0.72 (95% CI, 0.65 – 0.79) and 2.7 (95% CI, 2.1 – 3.5) for rs12150660 and rs6258, respectively
  • ...3 more annotations...
  • The risk of having low serum testosterone concentrations increased by the number of risk alleles with an OR of 1.62 (95% CI, 1.41 – 1.86) for each risk allele (Figure S4). Low serum testosterone concentrations were 6.5-times more prevalent in men with ≥3 risk alleles (30.1% prevalence of low serum testosterone) compared to men without any risk allele (4.6% prevalence of low serum testosterone;
  • SNP rs5934505 was associated with serum testosterone without SHBG-adjustment (combined p-value of 1.7×10−9) and with free testosterone (combined p-value of 6.7×10−15), but not with SHBG
  • The mean serum testosterone and calculated free testosterone but not SHBG concentrations were lower in men with T genotype than in those with C genotype for rs5934505
  • Nathan Goodyear on 19 Sep 17
     
    Genetic SNP rs5934505 associated with lower total Testosterone and lower calculated free Testosterone.  No effects on SHBG.
Nathan Goodyear

Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2... - 0 views

www.nature.com/...s41698-017-0044-8

cancer cancer stem cells liver cancer vitamin C IV vitamin C oncology

shared by Nathan Goodyear on 30 Jan 18 - No Cached
  • Chen et al. have revealed that ascorbate at pharmacologic concentrations (0.3–20 mM) achieved only by intravenously (i.v.) administration selectively kills a variety of cancer cell lines in vitro, but has little cytotoxic effect on normal cells.
  • Ascorbic acid (the reduced form of vitamin C) is specifically transported into cells by sodium-dependent vitamin C transporters (SVCTs)
  • SVCT-1 is predominantly expressed in epithelial tissues
  • ...41 more annotations...
  • whereas the expression of SVCT-2 is ubiquitous
  • differential sensitivity to VC may result from variations in VC flow into cells, which is dependent on SVCT-2 expression.
  • high-dose VC significantly impaired both the tumorspheres initiation (Fig. 4d, e) and the growth of established tumorspheres derived from HCC cells (Fig. 4f, g) in a time-dependent and dose-dependent manner.
  • Hepatocellular carcinoma (HCC)
  • The antioxidant, N-acetyl-L-cysteine (NAC), preventing VC-induced ROS production (a ROS scavenger), completely restored the viability and colony formation among VC-treated cells
  • DNA double-strand damage was found following VC treatment
  • DNA damage was prevented by NAC
  • Interestingly, the combination of VC and cisplatin was even more effective in reducing tumor growth and weight
  • Consistent with the in vitro results, stemness-related genes expressions in tumor xenograft were remarkably reduced after VC or VC+cisplatin treatment, whereas conventional cisplatin therapy alone led to the increase of CSCs
  • VC is one of the numerous common hepatoprotectants.
  • Interestingly, at extracellular concentrations greater than 1 mM, VC induces strong cytotoxicity to cancer cells including liver cancer cells
  • we hypothesized that intravenous VC might reduce the risk of recurrence in HCC patients after curative liver resection.
  • Intriguingly, the 5-year disease-free survival (DFS) for patients who received intravenous VC was 24%, as opposed to 15% for no intravenous VC-treated patients
  • Median DFS time for VC users was 25.2 vs. 18 months for VC non-users
  • intravenous VC use is linked to improved DFS in HCC patients.
  • In this study, based on the elevated expression of SVCT-2, which is responsible for VC uptake, in liver CSCs, we revealed that clinically achievable concentrations of VC preferentially eradicated liver CSCs in vitro and in vivo
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      the authors here made similar mistakes to the Mayo authors i.e. under doses here in this study.  They dosed at only 2 grams IVC.  A woefully low dose of IVC.
  • Additionally, we found that intravenous VC reduced the risk of post-surgical HCC progression in a retrospective cohort study.
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      positive results despite a low dose used.
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      Their comfort zone was 1mM.  They should have targeted 20-40 mM.
  • Three hundred thirty-nine participants (55.3%) received 2 g intravenous VC for 4 or more days after initial hepatectomy
  • As the key protein responsible for VC uptake in the liver, SVCT-2 played crucial roles in regulating the sensitivity to ascorbate-induced cytotoxicity
  • we also observed that SVCT-2 was highly expressed in human HCC samples and preferentially elevated in liver CSCs
  • SVCT-2 might serve as a potential CSC marker and therapeutic target in HCC
  • CSCs play critical roles in regulating tumor initiation, relapse, and chemoresistance
  • we revealed that VC treatment dramatically reduced the self-renewal ability, expression levels of CSC-associated genes, and percentages of CSCs in HCC, indicating that CSCs were more susceptible to VC-induced cell death
  • as a drug for eradicating CSCs, VC may represent a promising strategy for treatment of HCC, alone or particularly in combination with chemotherapeutic drugs
  • In HCC, we found that VC-generated ROS caused genotoxic stress (DNA damage) and metabolic stress (ATP depletion), which further activated the cyclin-dependent kinase inhibitor p21, leading to G2/M phase cell cycle arrest and caspase-dependent apoptosis in HCC cells
  • we demonstrated a synergistic effect of VC and chemotherapeutic drug cisplatin on killing HCC both in vitro and in vivo
  • Intravenous VC has also been reported to reduce chemotherapy-associated toxicity of carboplatin and paclitaxel in patients,38 but the specific mechanism needs further investigation
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      so, exclude the benefit to patients until the exact mechanism of action, which will never be fully elicited?!?!?
  • Our retrospective cohort study also showed that intravenous VC use (2 g) was related to the improved DFS in HCC patients after initial hepatectomy
    • Nathan Goodyear
      Nathan Goodyear on 31 Jan 18
       
      Terribly inadequate dose.  Target is 20-40 mM which other studies have found occur with 50-75 grams of IVC.
  • several clinical trials of high-dose intravenous VC have been conducted in patients with advanced cancer and have revealed improved quality of life and prolonged OS
  • high-dose VC was not toxic to immune cells and major immune cell subpopulations in vivo
  • high recurrence rate and heterogeneity
  • tumor progression, metastasis, and chemotherapy-resistance
  • SVCT-2 was highly expressed in HCC samples in comparison to peri-tumor tissues
  • high expression (grade 2+/3+) of SVCT-2 was in agreement with poorer overall survival (OS) of HCC patients (Fig. 1c) and more aggressive tumor behavior
  • SVCT-2 is enriched in liver CSCs
  • these data suggest that SVCT-2 is preferentially expressed in liver CSCs and is required for the maintenance of liver CSCs.
  • pharmacologic concentrations of plasma VC higher than 0.3 mM are achievable only from i.v. administration
  • The viabilities of HCC cells were dramatically decreased after exposure to VC in dose-dependent manner
  • VC and cisplatin combination further caused cell apoptosis in tumor xenograft
  • These results verify that VC inhibits tumor growth in HCC PDX models and SVCT-2 expression level is associated with VC response
  • qPCR and IHC analysis demonstrated that expression levels of CSC-associated genes and percentages of CSCs in PDXs dramatically declined after VC treatment, confirming the inhibitory role of VC in liver CSCs
  • Nathan Goodyear on 30 Jan 18
     
    IV vitamin C in vitro and in vivo found to "preferentially" eradicate cancer stem cells.  In addition, IV vitamin C was found to be adjunctive to chemotherapy, found to be hepatoprotectant.  This study also looked at SVCT-2, which is the transport protein important in liver C uptake.
Nathan Goodyear

Cellular Responses to Combinations of Hyperthermia and Radiation | Radiology - 0 views

pubs.rsna.org/...123.2.463

radiation cancer hyperthermia

shared by Nathan Goodyear on 20 Feb 21 - No Cached
  • Nathan Goodyear on 20 Feb 21
     
    Only abstract available here; but nice review of the combination effect of hyperthermia and radiation.
Nathan Goodyear

Frontiers | Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroac... - 0 views

www.frontiersin.org/...full

artesunate glioblastoma DCA

shared by Nathan Goodyear on 08 Jun 23 - No Cached
  • Nathan Goodyear on 08 Jun 23
     
    Hepatotoxicity associated with combination by these authors.
Nathan Goodyear

Factors of the ovarian cancer resistance to combined chemotherapy with platinum prepara... - 1 views

link.springer.com/...BF02445197

factors ovarian cancer resistance combined chemotherapy platinum glutathione

shared by Nathan Goodyear on 30 Jan 13 - No Cached
  • Nathan Goodyear on 30 Jan 13
     
    glutathione and ovarian cancer
Nathan Goodyear

Regulation of mitochondrial biogenesis by thyroid hormone - 0 views

ep.physoc.org/...121.full.pdf+html

T3 mitochondria thyroid hormone receptors TRH thyroid hormone response elements TRE hormone thyroid

shared by Nathan Goodyear on 29 Jun 13 - No Cached
  • Nathan Goodyear on 29 Jun 13
     
    Study describes the T3 effect on mitochondrial biogenesis.  T3 interacts with receptors involved with mitochondrial biogenesis in 3 ways: thyroid hormone receptors (TR), thyroid hormone receptor elements (TRE), and a combination of the two.
Nathan Goodyear

Metabolic Effects of Liothyronine Therapy in Hypothyroidism: A Randomized, Double-Blind... - 0 views

jcem.endojournals.org/...3466.abstract

T3 T4 hypothyroid hypothyroidism functional armour thyroid cholesterol LDL weight-loss overweight obesity metabolic effects therapy

shared by Nathan Goodyear on 08 Dec 11 - No Cached
  • Nathan Goodyear on 08 Dec 11
     
    T3 shown increase weight loss, lower LDL, decrease apolipoprotein B, decrease T cholesterol versus T4.  This flies in the face of conventional medical dogma, that T 4 (synthroid, levothyroxine) is the only route of thyroid replacement.  In fact, this suppports the use of armour thyroid, a T4/T3 combination.
Nathan Goodyear

The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer... - 0 views

www.ncbi.nlm.nih.gov/...PMC3162976

curcumin HER-2 breast cancer NF-KappaB

shared by Nathan Goodyear on 19 Jan 12 - No Cached
  • Nathan Goodyear on 19 Jan 12
     
    Curcumin downregulates HER-2 oncoprotein in breast cancer in vitro and in vivo.  IN this study, the combination of taxol and curcumin was comparable to that of taxol and perceptin.
Nathan Goodyear

Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels - NEJM - 0 views

www.nejm.org/...NEJMoa011364

homocysteine vitamin B12 B6 folic acid folate coronary angioplasty

shared by Nathan Goodyear on 25 Jul 12 - No Cached
  • Nathan Goodyear on 25 Jul 12
     
    lowering homocysteine reduced the rate of coronary restenosis.  A combination of folic acid, Vitamin B12, and Vitamin B6 were used to lower homocysteine.
Nathan Goodyear

Rapid determination of natural steroidal hormones in saliva for the clinical diagnoses - 0 views

www.ncbi.nlm.nih.gov/...PMC3351364

hormone hormones GC-MS saliva salivary testing

shared by Nathan Goodyear on 14 Aug 12 - No Cached
  • Nathan Goodyear on 14 Aug 12
     
    This study looked at combined sex hormone analysis via gas chromatography-mass spec.  Levels were able to be detected as low as 0.002 mcro/L in saliva.  This study validates the GC-MS for the use of multiple, simultaneous steroid hormone analysis
‹ Previous 21 - 40 of 275 Next › Last »
Showing 20▼ items per page